18F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer

Annals of Nuclear Medicine

Volumn 23, Issue 6, 2009, Pages 541-548

  Kwee, Sandi A ^a   Coel, Marc N ^a   Ly, Bevan H ^b   Lim, John ^a  

^a Hamamatsu/Queen's PET Imaging Center   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

Fluorocholine; Positron emission tomography; Prostate carcinoma

Indexed keywords

CHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; FEASIBILITY STUDY; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; TREATMENT RESPONSE; WHOLE BODY IMAGING;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CASE-CONTROL STUDIES; CHOLINE; HORMONES; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 68949101476     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-009-0273-1     Document Type: Article

References (26)

1. DP Petrylak CM Tangen MH Hussain PN Lara Jr JA Jones ME Taplin 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 1513 1520 10.1056/NEJMoa041318 (Pubitemid 39315318)
2. IF Tannock R de Wit WR Berry J Horti A Pluzanska KN Chi 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 1502 1512 10.1056/NEJMoa040720 (Pubitemid 39315317)
3. HI Scher MJ Morris WK Kelly LH Schwartz G Heller 2005 Prostate cancer clinical trial end points: "RECIST"ing a step backwards Clin Cancer Res 11 14 5223 5232 10.1158/1078-0432.CCR-05-0109 (Pubitemid 41003710)
4. PW Swindle MW Kattan PT Scardino 2003 Markers and meaning of primary treatment failure Urol Clin North Am 30 2 377 401 10.1016/S0094-0143(02)00176-3 (Pubitemid 36520609)
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16. doi: 10.1093/jnci/92.3.205. (Pubitemid 30099779)
6. K Glunde C Jie ZM Bhujwalla 2004 Molecular causes of the aberrant choline phospholipid metabolism in breast cancer Cancer Res 64 12 4270 4276 10.1158/0008-5472.CAN-03-3829 (Pubitemid 38802433)
7. A Ramirez de Molina A Rodriguez-Gonzalez R Gutierrez L Martinez-Pineiro J Sanchez F Bonilla 2002 Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers Biochem Biophys Res Commun 296 3 580 583 10.1016/S0006-291X(02)00920-8
8. M Heinisch A Dirisamer W Loidl F Stoiber B Gruy S Haim 2006 Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 8 1 43 48 10.1007/s11307-005-0023-2 (Pubitemid 44193401)
9. SA Kwee TR DeGrado JN Talbot F Gutman MN Coel 2007 Cancer imaging with fluorine-18-labeled choline derivatives Semin Nucl Med 37 6 420 428 10.1053/j.semnuclmed.2007.07.003 (Pubitemid 47498259)
10. DT Price RE Coleman RP Liao CN Robertson TJ Polascik TR DeGrado 2002 Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer J Urol 168 1 273 280 10.1016/S0022-5347(05)64906-3
11. TR DeGrado RE Coleman S Wang SW Baldwin MD Orr CN Robertson 2001 Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer Cancer Res 61 1 110 117
12. Lim J, Dorman E, Cabral C. Automated production of[18F]FECh and [18F]FCH: preparation and use of [18F]Fluoroalkane sulfonates and fluoroalkylation agents. J Labelled Comp Radiopharm. 2003;46:S46. doi: 10.1002/jlcr.757.
13. S Surti A Kuhn ME Werner AE Perkins J Kolthammer JS Karp 2007 Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities J Nucl Med 48 3 471 480
14. SA Kwee MN Coel J Lim JP Ko 2005 Prostate cancer localization with 18fluorine fluorocholine positron emission tomography J Urol 173 1 252 255
15. SA Kwee H Wei I Sesterhenn D Yun MN Coel 2006 Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET J Nucl Med 47 2 262 269
16. HI Scher S Halabi I Tannock M Morris CN Sternberg MA Carducci 2008 Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 7 1148 1159 10.1200/JCO.2007.12. 4487
17. Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol. 2006;176(5):2014-8. discussion 2018-2019. doi: 10.1016/j.juro.2006.07.037. (Pubitemid 44633154)
18. DB Husarik R Miralbell M Dubs H John OT Giger A Gelet 2008 Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 2 253 263 10.1007/s00259-007-0552-9
19. M Beheshti R Vali P Waldenberger F Fitz M Nader W Loidl 2008 Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study Eur J Nucl Med Mol Imaging 35 10 1766 1774 10.1007/s00259-008-0788-z
20. H Vees F Buchegger S Albrecht H Khan D Husarik H Zaidi 2007 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy BJU Int 99 6 1415 1420 10.1111/j.1464-410X.2007.06772.x (Pubitemid 47164795)
21. B Tombal A Rezazadeh P Therasse PJ Van Cangh B Vande Berg FE Lecouvet 2005 Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases Prostate 65 2 178 187 10.1002/pros.20280 (Pubitemid 41362285)
22. SD Yeh M Imbriaco SM Larson D Garza JJ Zhang H Kalaigian 1996 Detection of bony metastases of androgen-independent prostate cancer by PET-FDG Nucl Med Biol 23 6 693 697 10.1016/0969-8051(96)00044-3 (Pubitemid 26342473)
23. PD Shreve HB Grossman MD Gross RL Wahl 1996 Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose Radiology 199 3 751 756
24. R Nunez HA Macapinlac HW Yeung T Akhurst S Cai I Osman 2002 Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer J Nucl Med 43 1 46 55
25. Y Zhang M Saylor S Wen MD Silva M Rolfe J Bolen 2006 Longitudinally quantitative 2-deoxy-2-[18F]fluoro-d-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model Mol Imaging Biol 8 5 300 308 10.1007/s11307-006- 0052-5 (Pubitemid 44446024)
26. MJ Morris T Akhurst SM Larson M Ditullio E Chu K Siedlecki 2005 Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy Clin Cancer Res 11 9 3210 3216 10.1158/1078-0432.CCR-04-2034 (Pubitemid 40627867)